News

In a major shake-up that’s bound to impact millions of patients, CVS Caremark is cutting ties with Eli Lilly’s weight loss drug Zepbound—and making Novo Nordisk’s Wegovy the go-to GLP-1 for obesity treatment. If your insurance runs through CVS Caremark, here’s what’s changing, why it’s happening, and what you should do next.

The landscape of diabetes and obesity management is on the cusp of a significant transformation, driven by the development of oral...

The World Health Organization (WHO) is getting ready to make a move that could reshape how the world handles obesity. For the first time,...

With demand for GLP-1 medications like semaglutide and tirzepatide soaring, clinical trials have quietly become one of the only ways some people can access treatment, especially if they’re uninsured or can’t afford retail prices. But before you go signing up for an experimental dose of the next Ozempic or peptide agonist, there are a few important things to understand. In this article, we'll talk about what clinical trials are, their pros and cons, what to expect, and how to

Retatrutide is being called the “triple threat” of weight loss drugs—and it’s not even on the market yet. Developed by Eli Lilly, the same pharmaceutical giant behind tirzepatide (better known as Mounjaro and Zepbound), this new contender is generating buzz for its potential to help people lose more weight, faster.

What I found was both wild and well-documented: the gut—yes, your gut—may be deeply involved in how osteoarthritis develops and how it could be treated. A hormone called GLP-1, best known for regulating digestion and appetite, might also protect cartilage and reduce joint inflammation. Researchers call it the gut-joint axis, and it’s changing the way we think about osteoarthritis.

The window for GLP-1 compounders to tap dance around the compounding ban is almost closed — and anyone still trying to squeeze through could end up with some bruised fingers. A federal court ruling has backed the FDA’s determination that shortages of Wegovy and Ozempic are officially over, setting up a sharp end to the era of legally available compounded GLP-1s.

Starting a GLP-1 journey can feel overwhelming — not just because of the medication, but because of the new language that comes with it....

In this guide, we’re cutting through the noise and calling out the most common GLP-1 myths for what they are—subjective and sometimes silly.

My first attempt to get Zepbound through LillyDirect at the discounted price felt like a triangulated game of "Who's On First?" I faced a...

Eli Lilly, the pharmaceutical giant, filed a sweeping set of lawsuits in federal court, accusing four telehealth startups—Mochi Health, Fella Health, Empower Pharmacy, and Henry Meds—of illegally selling off-brand, compounded versions of its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro.

The battle over compounded versions of blockbuster weight-loss drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro,...

As demand for GLP-1 medications like Ozempic (semaglutide) continues to surge in the U.S., the Food and Drug Administration (FDA) and...